Evidence map›Paper›PMID 39917335›Full record

ArticleOpen forum infectious diseases2025

Viral Burden and Illness Severity During Acute SARS-CoV-2 Infection Predict Persistent Long COVID Symptoms.

Elisabeth Brandstetter Figueroa, Anne E P Frosch, Kristina S Burrack, Gayathri Dileepan, Rachael Goldsmith, Morgan Harris, Nwando Ikeogu, Hodan Jibrell, Sangeitha Thayalan, Robin L Dewar and 3 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Elisabeth Brandstetter FigueroaDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-0521-4131
Anne E P FroschDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-1850-8913
Kristina S BurrackDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-6931-226X
Gayathri DileepanDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-6252-4414
Rachael GoldsmithDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
Morgan HarrisDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-3821-5931
Nwando IkeoguDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0009-0006-5660-2774
Hodan JibrellDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
Sangeitha ThayalanDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
Robin L DewarFrederick National Laboratory, Leidos Biomedical Research, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0002-7840-3155
Chetan ShenoyDepartment of Medicine, School of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-8877-4999
Irini SeretiDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-0076-0224
Jason V BakerDivision of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.

Funding

Immunologic basis of cardiac disease after severe COVID-19R01HL158756 · NHLBI · UNIVERSITY OF MINNESOTA · PI BAKER, JASON V, SHENOY, CHETAN · 2022 to 2025
$2.7M
NHLBI NIH HHS R01 HL158756
6 · The paper itself

Abstract

Background: Long COVID is a common complication of infection with severe acute respiratory syndrome coronavirus 2, but the prevalence and predictors of the condition remain poorly characterized. Methods: We prospectively studied adults (≥18 years) with acute coronavirus disease 2019 (COVID-19) presenting to an urban safety net hospital and associated clinics between July 2020 and December 2022. Logistic regression models were used to evaluate the association between baseline demographic, clinical, and laboratory characteristics with long COVID status, defined as symptoms persisting at least 9 months after acute disease. Among unrecovered participants, we describe the prevalence of individual symptoms. Results: We enrolled 222 participants, 162 (73%) of whom had known recovery status by 9 months. Median age was 54 years, half (55%) were female, and the majority of participants (78%) had at least 1 comorbidity at the time of COVID-19 diagnosis. Based on acute illness characteristics, the adjusted odds ratio for long COVID was 3.0 (95% confidence interval [CI], 1.1-8.0) among those with detectable nucleocapsid antigen and 3.6 (95% CI, 1.2-11) for those who required supplemental oxygen. Of the 41% of participants with symptoms persisting at least 9 months, central nervous system and psychological symptoms were most commonly reported, with 57% reporting functional limitations due to their persistent symptoms. Conclusions: The strong association with initial disease suggests a decreasing prevalence of long COVID as acute illnesses become milder. However, many contemporary patients still experience high viral burden with extended viral replication, even after vaccination. Our findings highlight the importance of properly characterizing long COVID as viral evolution shifts acute disease presentation.

Indexed as

COVID-19long COVIDpost-acute sequelae of SARS-CoV-2 infection (PASC)SARS-CoV-2viral burden

Identifiers

PMID39917335
PMCPMC11800476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.